Kinnate Biopharma Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 32.94 million compared to USD 26.9 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 0.61 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | -0.38% | -.--% | +11.81% |
03/04 | Kinnate Biopharma Inc. Announces Board Resignations | CI |
03/04 | Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
+11.81% | 13Cr | |
+29.03% | 4.92TCr | |
-0.10% | 4.21TCr | |
+49.45% | 4.04TCr | |
-5.26% | 2.89TCr | |
+11.48% | 2.61TCr | |
-22.74% | 1.87TCr | |
+9.06% | 1.33TCr | |
+30.01% | 1.23TCr | |
-1.51% | 1.2TCr |
- Stock Market
- Equities
- KNTE Stock
- News Kinnate Biopharma Inc.
- Kinnate Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023